Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-07Est. Completion: 2029-10-01
Enrollment target: 131 participants
Locations
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham, Alabama, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
NYU Longone Health, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Hospital Esslingen GmbH, Esslingen am Neckar, Baden-Wurttemberg, Germany
University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology/ Clinical Immunology, Würzburg, Bavaria, Germany
Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift, Bielefeld, North Rhine-Westphalia, Germany
Clinics Essen-Mitte, Essen, North Rhine-Westphalia, Germany
Foundation Bethanien Moers, Moers, North Rhine-Westphalia, Germany
Institute of Romagna for Cancer Research "Dino Amadori" - IRCCS IRST, Forlì, Emilia-Romagna, Italy
Oncology Reference Center, Aviano, Friuli Venezia Giulia, Italy
National Cancer Institute Regina Elena, IRCCS, Rome, Lazio, Italy
Other microbiome trials you might be interested in